Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
OwnerLeland F. Wilson, Virgil A. Placeinventors
Life of this patent
Estimating the term…
Abstract
Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal polypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. Pharmaceutical formulations and kits are also provided.
Claims40
A method for treating sexual dysfunction in a female individual, comprising administering to the vagina and/or vulvar region of the individual a pharmaceutical formulation that comprises a therapeutically effective amount of a vasoactive agent selected from the group consisting vasoactive intestinal polypeptide and agonists thereof.
A method for enhancing sexual desire and responsiveness in a female individual, comprising administering to the individual, approximately 0.25 to 72 hours prior to sexual activity, a therapeutically effective amount of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof.
A method for maintaining improving the tissue health of the female genitalia, comprising administering to a female individual, on an as-needed basis, a therapeutically effective amount of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof.
A method for preventing vaginal atrophy, comprising administering to a female individual, on an as-needed basis, a therapeutically effective amount of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof.
A method for preventing vaginal pain during sexual intercourse, comprising administering to a female individual suffering from dyspareunia a therapeutically effective amount of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof.
A method for alleviating vaginal itching and dryness, comprising administering to a female individual in need of such treatment a therapeutically effective amount of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof, on an as-needed basis.
A method for enhancing sexual desire and responsiveness in a female individual, comprising administering a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof to the individual in an amount effective to provide a blood level of the agent or a metabolite thereof that approximates the blood level of the agent or a metabolite thereof during ovulation.
A pharmaceutical formulation for enhancing female sexual desire and responsiveness, comprising (a) approximately 1.0 μg to 1.0 g of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide, agonists thereof, and combinations thereof, per gram of formulation, (b) a pharmaceutically acceptable carrier suitable for vaginal and/or vulvar administration.
A packaged kit for a female individual to use in enhancing sexual desire and responsiveness, comprising:
- a pharmaceutical formulation of a vasoactive agent selected from the group consisting of vasoactive intestinal polypeptide and agonists thereof;
- a container housing the pharmaceutical formulation during storage and prior to administration;
- and instructions for carrying out drug administration to enhance sexual desire and responsiveness.
Dependencies are inferred from the claim text.